Saum Ghodoussipour, MD, PhD, dissected the contrasting outcomes between adjuvant durvalumab plus tremelimumab compared with durvalumab alone in RCC.
Saum Ghodoussipour, MD
Advertisement
Articles by Saum Ghodoussipour, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
ASCO 2026: Dynamic Therapy Interventions With PSMA in Metastatic HSPC
2
ASCENT-04 Data Yields Longer PFS2 in Previously Untreated Metastatic TNBC
3
Ivonescimab Combo Yields Encouraging Activity in Previously Treated SCLC
4
Camrelizumab Plus Rivoceranib/TACE Improve PFS, Increases Toxicity in uHCC
5